Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need

Journal of Drug Targeting

Volumn 27, Issue 1, 2019, Pages 12-27

  Patil, Tulshidas S ^a   Deshpande, Ashwini S ^a   Deshpande, Shirish ^a   Shende, Pravin ^b  

^a School of Pharmacy and Technology Management   (India)

^b SVKM s Narsee Monjee Institute of Management Studies   (India)

Author keywords

drug targeting; lipid nanocarriers; nanocarrier based DPIs; Pulmonary tuberculosis; surface engineering

Indexed keywords

CATION; LIPOSOME; MICROSPHERE; NANOCARRIER; POLYMER; SOLID LIPID NANOPARTICLE; TUBERCULOSTATIC AGENT; DRUG CARRIER; LIPID; NANOMATERIAL;

CHEMICAL STRUCTURE; DRUG TARGETING; DRY POWDER; FREEZE DRYING; HUMAN; LIPOSOMAL DELIVERY; LUNG TUBERCULOSIS; MICELLE; NANOENCAPSULATION; NANOPHARMACEUTICS; POLYMERIZATION; POROSITY; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRY POWDER INHALER; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MYCOBACTERIUM TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LIPIDS; MYCOBACTERIUM TUBERCULOSIS; NANOSTRUCTURES; TUBERCULOSIS, PULMONARY;

EID: 85044711262     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/1061186X.2018.1455842     Document Type: Review

References (98)

1. Tiberi S, Buchanan R, Caminero JA, et al. The challenge of the new tuberculosis drugs. Presse Med. 2017;46:e41–e51.
2. WHO. Global Tuberculosis Report. Geneva: World Health Organization; 2016.
3. Velayati AA, Farnia P, Farahbod AM., Overview of drug-resistant tuberculosis worldwide. Int J Mycobacteriol. 2016;5:S161.
4. WHO-Tuberculosis-End TB Strategy-Global strategy and targets for tuberculosis prevention, care and control after 2015 [Internet]. Geneva: World Health Organization; 2015 [cited 2017 Jul 22]; [about 1 screens]. Available from: http://www.who.int/tb/post2015_strategy/en/
5. Jamwal SV, Mehrotra P, Singh A, et al. Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism. Sci Rep. 2017;6:23089.
6. Cirillo SLG, Subbian S, Chen B, et al. Protection of Mycobacterium tuberculosis from reactive oxygen species conferred by the mel2 locus impacts persistence and dissemination. Infect Immun. 2009;77:2557–2567.
7. Vandal OH, Nathan CF, Ehrt S., Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009;191:4714–4721.
8. Ferrari G, Langen H, Naito M, et al. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell. 1999;97:435–447.
9. CDC. Questions and answers about tuberculosis [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2014 [cited 2017 Jul 22]; Available from: https://www.cdc.gov/tb/publications/faqs/pdfs/qa.pdf
10. Da Silva PEA, Von Groll A, Martin A, et al. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol. 2011;63:1–9.
11. Balganesh M, Dinesh N, Sharma S, et al. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob Agents Chemother. 2012;56:2643–2651.
12. Rossi ED, Aínsa JA, Riccardi G., Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev. 2006;30:36–52.
13. Palomino JC, Martin A., Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics. 2014;3:317–340.
14. Tiberi S, Scardigli A, Centis R, et al. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 2017;56:181–184.
15. Maitre T, Aubry A, Jarlier V, et al. Multidrug and extensively drug-resistant tuberculosis. Med Mal Infect. 2017;47:3–10.
16. Nasiruddin M, Neyaz MK, Das S, et al. Nanotechnology-based approach in tuberculosis treatment. Tuberc Res Treat. 2017;2017:4920209.
17. Weber S, Zimmer A, Pardeike J., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86:7–22.
18. Muralidharan P, Malapit M, Mallory E, et al. Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine. 2015;11:1189–1199.
19. Hidalgo A, Cruz A, Pérez-Gil J., Barrier or carrier? Pulmonary surfactant and drug delivery. Eur J Pharm Biopharm. 2015;95:117–127.
20. Parumasivam T, Chang RYK, Abdelghany S, et al. Dry powder inhalable formulations for anti-tubercular therapy. Adv Drug Deliv Rev. 2016;102:83–101.
21. Costa A, Pinheiro M, Magalhães J, et al. The formulation of nanomedicines for treating tuberculosis. Adv Drug Deliv Rev. 2016;102:102–115.
22. Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014; 75:18–31.
23. Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm. 2014;86:23–30.
24. de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14:499–512.
25. Mehta P., Dry powder inhalers: a focus on advancements in novel drug delivery systems. J Drug Deliv. 2016;2016:1–16.
26. Doktorovová S, Kovačević AB, Garcia ML, et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;108:235–252.
27. Boverhof DR, Bramante CM, Butala JH, et al. Comparative assessment of nanomaterial definitions and safety evaluation considerations. Regul Toxicol Pharmacol. 2015;73: 137–150.
28. Gwinn MR, Vallyathan V., Nanoparticles: health effects–pros and cons. Environ Health Perspect. 2006;114:1818.
29. Rojanarat W, Changsan N, Tawithong E, et al. Isoniazid proliposome powders for inhalation–preparation, characterization and cell culture studies. IJMS. 2011;12:4414–4434.
30. Changsan N, Nilkaeo A, Pungrassami P, et al. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages. J Drug Target. 2009;17:751–762.
31. Patil JS, Devi VK, Devi K, et al. A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis. Lung India. 2015;32: 331–338.
32. Patil-Gadhe A, Pokharkar V., Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach. Pulm Pharmacol Ther. 2014;27:197–207.
33. Pokharkar V, Patil-Gadhe A, Kyadarkunte A, et al. Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity. Toxicol Int. 2014;21:275–282.
34. Rojanarat W, Nakpheng T, Thawithong E, et al. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv. 2012;19:334–345.
35. Eedara BB, Tucker IG, Das SC., Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis. Int J Pharm. 2016;506:174–183.
36. Rojanarat W, Nakpheng T, Thawithong E, et al. Levofloxacin-proliposomes: opportunities for use in lung tuberculosis. Pharmaceutics. 2012;4:385–412.
37. Shah SP, Misra A., Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech. 2004;5:107–113.
38. Manca ML, Valenti D, Sales OD, et al. Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin. Int J Pharm. 2014;472: 102–109.
39. Pourshahab PS, Gilani K, Moazeni E, et al. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsul. 2011;28:605–613.
40. Rawal T, Parmar R, Tyagi RK, et al. Rifampicin loaded chitosan nanoparticle dry powder presents: an improved therapeutic approach for alveolar tuberculosis. Colloids Surf B Biointerfaces. 2017;154:321–330.
41. Kundawala AJ, Patel VA, Patel HV, et al. Preparation of microparticles containing rifampicin as dry powder formulation: in vitro studies on aerosol performance. Am J PharmTech Res. 2012;2:470–483.
42. Pai RV, Jain RR, Bannalikar AS, et al. Development and evaluation of chitosan microparticles based dry powder inhalation formulations of rifampicin and rifabutin. J Aerosol Med Pulm D. 2016;29:179–195.
43. Kundawala AJ, Patel VA, Patel HV, et al. Treating tuberculosis with Chitosan microparticles loaded with rifampicin as respirable powder for pulmonary delivery. Ind J Nov Drug Deliver 2012;4:57–65.
44. Kundawala A, Patel V, Patel H, et al. Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin. Sci Pharm. 2014;82:665–682.
45. Lawlor C, O’Sullivan MP, Rice B, et al. Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb). J Mater Sci Mater Med. 2012;23:89–98.
46. Parumasivam T, Leung SSY, Quan DH, et al. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: preparation and in vitro aerosol characterization. Eur J Pharm Sci. 2016;88:1–11.
47. Kundawala AJ, Patel V, Patel HV, et al. Isoniazid loaded chitosan microspheres for pulmonary delivery: preparation and characterization. Pharm Sin. 2011;2:88–97.
48. Doan TVP, Couet W, Olivier JC., Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int J Pharm. 2011; 414:112–117.
49. Doan TVP, Olivier JC., Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization. Int J Pharm. 2009;382:61–66.
50. Ohashi K, Kabasawa T, Ozeki T, et al. One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release. 2009;135:19–24.
51. Coowanitwong I, Arya V, Kulvanich P, et al. Slow release formulations of inhaled rifampin. AAPS J. 2008;10:342–348.
52. O'hara P, Hickey AJ., Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000;17:955–961.
53. Diab R, Brillault J, Bardy A, et al. Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting. Int J Pharm. 2012;436:833–839.
54. Gaspar MC, Sousa JJS, Pais AACC, et al. Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. Eur J Pharm Biopharm. 2015;96: 65–75.
55. Ventura CA, Tommasini S, Crupi E, et al. Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies. Eur J Pharm Biopharm. 2008;68:235–244.
56. Mizoe T, Ozeki T, Okada H., Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitolmicroparticles. AAPS PharmSciTech. 2008;9:755–761.
57. Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009; 26:1847–1855.
58. Kho K, Hadinoto K., Optimizing aerosolization efficiency of dry-powder aggregates of thermally-sensitive polymeric nanoparticles produced by spray-freeze-drying. Powder Technol. 2011;214:169–176.
59. Son YJ, McConville JT., Preparation of sustained release rifampicin microparticles for inhalation. J Pharm Pharmacol. 2012;64:1291–1302.
60. Vadakkan MV, Annapoorna K, Sivakumar KC, et al. Dry powder cationic lipopolymericnanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage. Int J Nanomedicine. 2013;8:2871–2885.
61. Darbandi MA, Rouholamini N, Gilani K, et al. The effect of vehicles on spray drying of rifampicin inhalable microparticles: in vitro and in vivo evaluation. DARU. 2008;16: 128–135.
62. Duan J, Vogt FG, Li X, et al. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int J Nanomedicine. 2013;8:3489–3505.
63. Lee SH, Teo J, Heng D, et al. Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation. Eur J Pharm Biopharm. 2013;83:275–284.
64. Momin MAM, Sinha S, Tucker IG, et al. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. Int J Pharm. 2017;528: 107–117.
65. Manion JR, Cape SP, McAdams DH, et al. Inhalable antibiotics manufactured through use of near-critical or supercritical fluids. Aerosol Sci Technol. 2012;46:403–410.
66. Schoubben A, Giovagnoli S, Tiralti MC, et al. Capreomycin inhalable powders prepared with an innovative spray-drying technique. Int J Pharm. 2014;469:132–139.
67. Fiegel J, Garcia-Contreras L, Thomas M, et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res. 2008;25:805–811.
68. Garcia-Contreras L, Padilla-Carlin DJ, Sung J, et al. Pharmacokinetics of ethionamide delivered in spray-dried microparticles to the lungs of guinea pigs. J Pharm Sci. 2017;106:331–337.
69. Verma RK, Germishuizen WA, Motheo MP, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother. 2013;57:1050–1052.
70. Gad S, Tajber L, Corrigan OI, et al. Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state. J Pharm Pharmacol. 2012;64: 1264–1274.
71. Tsapis N, Bennett D, O’Driscoll K, et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb). 2003;83:379–385.
72. Yadav A, Murthy MS, Shete AS, et al. Stability aspects of liposomes. IJPER. 2011;45:402–413.
73. Infectex-Maxwell Biotech Group. Infectex successfully completes phase 1 clinical study of Q203 for treatment of tuberculosis [Internet]. Moscow: Infectex-Maxwell Biotech Group; [cited 2018 Feb 02]; [about 1 screens]. Available from: http://infectex.ru/en/%D0%B1%D0%B5%D0%B7-%D1%80%D1%83%D0%B1%D1%80%D0%B8%D0%BA%D0% B8-en/infectex-successfully-completes-phase-1-clinical-study-of-q203-for-treatment-of-tuberculosis/
74. Infectex-Maxwell Biotech Group. Infectex announces positive phase 2b-3 clinical trial results of SQ109 for the treatment of multidrug-resistant pulmonary tuberculosis [Internet]. Moscow: Infectex-Maxwell Biotech Group; [cited 2018 Feb 02]; [about 1 screens]. Available from: http://infectex.ru/en/%D0%B1%D0%B5%D0%B7-%D1%80%D1%83% D0%B1%D1%80%D0%B8%D0%BA%D0%B8-en/infectex-announces-positive-phase-2b-3-clinical-trial-results-of-sq109-for-the-treatment-of-multidrug-resistant-pulmonary-tuberculosis/
75. Traini D, Paul MY., Drug delivery for tuberculosis: is inhaled therapy the key to success? Ther Deliv. 2017;8:819–821.
76. DR-TB clinical trials progress report [Internet]. Cambridge (MA): RESIST-TB: Research Excellence to Stop TB Resistance; [cited 2018 Feb 02]; [about 2 screens]. Available from: http://www.resisttb.org/?page_id=1602
77. Ibrahim M, Verma R, Garcia-Contreras L., Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–139.
78. Crowder TM, Donovan MJ., Controlled pulmonary drug delivery: science and technology of dry powder inhalers. New York (NY): Springer; 2011.
79. Ashurst I, Malton A, Prime D, et al. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today. 2000;3:246–256.
80. Warheit DB., Nanoparticles: health impacts? Mater Today. 2004;7:32–35.
81. 2 nanoparticles toward human lung epithelial cells. Sci Total Environ. 2011;409:1219–1228.
82. Hussain S, Boland S, Baeza-Squiban A, et al. Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount. Toxicology. 2009;260:142–149.
83. Jiménez-Lamana J, Laborda F, Bolea E, et al. An insight into silver nanoparticles bioavailability in rats. Metallomics. 2014;6:2242–2249.
84. Hickey AJ, Misra A, Fourie PB., Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J Pharm Sci. 2013;102:3900–3907.
85. US Food and Drug Administration/Center for Drug Evaluation and Research (USFDA/CDER). Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route, Guidance for Industry and Review Staff, Good Review Practice. Silver Spring (MD): USFDA/CDER; 2015:1–12.
86. Naseri N, Valizadeh H, ZakeriMilani P., Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5:305–313.
87. Das S, Ng WK, Tan RBH., Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012; 47:139–151.
88. Kaur P, Garg T, Rath G, et al. Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design. Drug Deliv. 2016;23:1912–1925.
89. Xia D, Shrestha N, van de Streek J, et al. Spray drying of fenofibrate loaded nanostructured lipid carriers. Asian J Pharm Sci. 2016;11:507–515.
90. Jyoti K, Kaur K, Pandey RS, et al. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies. J Colloid Interf Sci. 2015;445:219–230.
91. Patil-Gadhe A, Kyadarkunte A, Patole M, et al. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro–in vivo aerosol performance. Eur J Pharm Biopharm. 2014;88:169–177.
92. Patil-Gadhe A, Pokharkar V., Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: optimization by factorial design. Int J Pharm. 2016;501:199–210.
93. Moreno-Sastre M, Pastor M, Esquisabel A, et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. J Microencapsul. 2016;33:636–645.
94. Pinheiro M, Ribeiro R, Vieira A, et al. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des Devel Ther. 2016;10:2467–2475.
95. Song X, Lin Q, Guo L, et al. Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery. Pharm Res. 2015;32:1741–1751.
96. Sato MR, Oshiro Junior JA, Machado RTA, et al. Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis. Drug Des Devel Ther. 2017;11:909–921.
97. Jones BG, Dickinson PA, Gumbleton M, et al. The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages. Int J Pharm. 2002;236:65–79.
98. Patel B, Gupta N, Ahsan F. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. Eur J Pharm Biopharm. 2014;89:163–174.